One limitation of the current study is its reliance on the RPΔG genetically engineered mouse model, which primarily recapitulates small cell lung cancer (SCLC) driven by the deletion of RB1 and TP53 genes. This evidence concerns the gene TP53 and small cell lung carcinoma.